Newsroom

Healthcare Pharmaceutical Biotech

Stay informed with the latest in Healthcare, Pharmaceutical and Biotech press releases through our newsroom. Explore breaking updates, industry trends, and insights shaping these vital sectors—all in one place. Whether it’s innovation, regulatory changes, or breakthroughs, our newsroom keeps you connected to the stories that matter most.


Latest Press Releases

Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump
Healthcare & PharmaceuticalProduct Announcements

Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump

November 17, 2025 8:30 AM

Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a leader in innovative insulin delivery technology targeting the $3 billion adult "almost-pumpers" diabetes market with user-friendly, affordable patch pumps, today announced Institutional Review Board ("IRB") approval to conduct an in-house study of its next-generation Pivot™ insulin delivery system using insulin on people with diabetes (the "Study"). Pursuant to U.S....

Read more
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
Healthcare & PharmaceuticalEarnings

NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position

November 17, 2025 8:30 AM

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange Commission (SEC) on Friday, November 14, 2025. The report can be accessed at the SEC website (https://www.sec.gov/Archives/edgar/data/1379006/000110465925112608/nnvc-20250930x10q.htm). Clinical Stage NV-387, a Single Drug, Meets Many Unmet Medical...

Read more
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
Healthcare & PharmaceuticalCompany Update

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

November 17, 2025 8:05 AM

Ensysce Biosciences, Inc. (NASDAQ:ENSC)("Ensysce" or the "Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the closing of a $4 million convertible preferred stock financing, with upside to potentially $16 million of additional funding available through future tranches over the next 24 months. The capital will accelerate the Phase 3 clinical program for PF614, Ensysce's flagship...

Read more
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Healthcare & PharmaceuticalEarnings

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

November 17, 2025 8:00 AM

Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported its consolidated third-quarter 2025 financial results. 2025 THIRD QUARTER COMPANY FINANCIAL RESULTS: Net Revenue: The combined net revenue for the Company's prescription products (Mytesi®, Gelclair®, and Canalevia®-CA1), including license revenue, was approximately $3.1 million in the third quarter of 2025, representing an increase of approximately 4% over the combined...

Read more
Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin
Healthcare & PharmaceuticalCompany Update

Medicus Pharma Ltd. Announces Filing of FDA Commissioner's National Priority Voucher Application (CNPV) for SKNJCT-003 to Non-Invasively Treat Basal Cell Carcinoma (BCC) of the Skin

November 17, 2025 7:30 AM

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics assets, is pleased to announce that it has submitted an FDA Commissioner's national priority voucher (CNPV) application on behalf of Skinject (SKNJCT-003) evaluating Doxorubicin Microneedle Array (D-MNA) to non-invasively treat basal cell carcinoma...

Read more
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma
Healthcare & PharmaceuticalCompany Update

OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma

November 17, 2025 7:00 AM

OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the...

Read more
Wellgistics Health to Report Third Quarter 2025 Financial Results and Provide a Business Update on the morning of Thursday, November 20th, 2025
Healthcare & PharmaceuticalCompany Update

Wellgistics Health to Report Third Quarter 2025 Financial Results and Provide a Business Update on the morning of Thursday, November 20th, 2025

November 17, 2025 6:00 AM

Wellgistics Health, Inc. ("Wellgistics") (NASDAQ:WGRX), a health information technology leader at the nexus of the physical and technology healthcare infrastructures for prescription drug distribution from manufacturer to patient through licensed pharmacies, today announced that it will report third quarter 2025 provide a business update and report financial results for the period ended September 30, 2025 on the morning of Thursday, November 20,...

Read more
iZafe Group's Business Unit Manager, Helena Kolvik, Acquires Shares in the Company
Healthcare & PharmaceuticalCompany Update

iZafe Group's Business Unit Manager, Helena Kolvik, Acquires Shares in the Company

November 17, 2025 4:15 AM

iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ.) announces today that the company's Business Unit Manager, Helena Kolvik, has acquired approximately 158,500 B-shares in iZafe, corresponding to a total value of approximately SEK 100,000. The acquisitions were carried out on two occasions, last Friday and today. The acquisitions underline Helena's strong commitment to iZafe Group's operations and her confidence in the company's continued...

Read more
Innerbloom Ketamine Therapy Expands Depression Treatment in San Luis Obispo With FDA-Approved SPRAVATO
Healthcare & PharmaceuticalCompany Update

Innerbloom Ketamine Therapy Expands Depression Treatment in San Luis Obispo With FDA-Approved SPRAVATO

November 16, 2025 9:00 PM

Innerbloom Ketamine Therapy announces the addition of SPRAVATO® (esketamine) nasal spray to its comprehensive mental health treatment offerings, providing San Luis Obispo residents access to an FDA-approved treatment for treatment-resistant depression that can now be used with or without a daily oral antidepressant. Earlier this year, SPRAVATO® received FDA approval as the first and only medication for treating treatment-resistant depression...

Read more
President Trumps Cannabis Decision Soon: From Hemp Shutdown to Pharmaceutical Clarity: MMJ Leads Federally Legal Cannabis Drug Development
Healthcare & PharmaceuticalCompany Update

President Trumps Cannabis Decision Soon: From Hemp Shutdown to Pharmaceutical Clarity: MMJ Leads Federally Legal Cannabis Drug Development

November 16, 2025 5:00 PM

As Congress moves decisively to end the era of intoxicating hemp products and synthetic cannabinoids, a new chapter is opening for federally legal cannabis based medicines. With regulatory clarity emerging from the FDA, DEA, and bipartisan state authorities, MMJ International Holdings, Inc. now stands as the U.S. company fully positioned within the federal pharmaceutical pathway for cannabis drug development. For a decade, MMJ pursued the...

Read more
Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review
Healthcare & PharmaceuticalCompany Update

Ascelia Pharma Announces FDA Acceptance of Orviglance New Drug Application for Review

November 15, 2025 6:15 AM

Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for Orviglance® for review. The FDA has set an action date of 3 July 2026 under the Prescription Drug User Fee Act (PDUFA). The FDA has confirmed through their ‘day 74 letter' their acceptance of the NDA filing for...

Read more
Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights
Healthcare & PharmaceuticalEarnings

Medicus Pharma Ltd. Provides Corporate Updates and Reports Third Quarter 2025 Financial Highlights

November 14, 2025 5:00 PM

Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic assets, announced today its financial and operating results for the quarter ending September 30, 2025, and highlighted important corporate updates. Third Quarter Corporate Highlights: Skinject Clinical Development Program SKNJCT-003 & SKNJCT-004...

Read more
ADM Tronics Reports Second Quarter of Fiscal Year 2026 Results
Healthcare & PharmaceuticalEarnings

ADM Tronics Reports Second Quarter of Fiscal Year 2026 Results

November 14, 2025 4:35 PM

ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its second fiscal quarter ended September 30, 2025 of Fiscal Year 2026. The Company continued its positive momentum in revenues this fiscal year, building on the gains reported in the Annual 10-K Report for the fiscal year ended March 31, 2025, and the first fiscal quarter ended June 30, 2025. For...

Read more
Tivic Reports Third Quarter 2025 Financial Results
Healthcare & PharmaceuticalEarnings

Tivic Reports Third Quarter 2025 Financial Results

November 14, 2025 4:30 PM

Tivic Health® Systems, Inc. (Nasdaq:TIVC), a diversified immunotherapeutics company, today announced financial results for the third quarter and nine months ended September 30, 2025 and provided a business update. "Following our discussions at the Military Health System Research Symposium and continued engagement with key government agencies, we are encouraged by the interest in our lead product candidate, Entolimod for acute radiation syndrome...

Read more
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
Healthcare & PharmaceuticalEarnings

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

November 14, 2025 4:15 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation severe pain therapeutics designed to minimize abuse and overdose risk, today reported financial and operational results for the third quarter ended September 30, 2025. Dr. Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "It has been another highly productive quarter as we navigate tumultuous...

Read more
CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results
Healthcare & PharmaceuticalEarnings

CASI Pharmaceuticals Announces Third Quarter 2025 Business and Financial Results

November 14, 2025 4:05 PM

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on the development of CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today reported business and financial results for the quarter ended September 30, 2025 (the "third quarter"). "We are focused on capitalizing and advancing our CID-103 clinical program in renal...

Read more
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
Healthcare & PharmaceuticalEarnings

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

November 14, 2025 4:05 PM

Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the third quarter ended September 30, 2025. "At Dermata, our mission is to bring scientifically developed innovation directly to those who need it most," said Gerry Proehl, Chairman, President, and CEO of Dermata. "Our recent strategic...

Read more
Cenmed and Curavit Announce Strategic Collaboration to Streamline Clinical Trial Kitting and Logistics
Healthcare & PharmaceuticalPartnerships

Cenmed and Curavit Announce Strategic Collaboration to Streamline Clinical Trial Kitting and Logistics

November 14, 2025 3:00 PM

Cenmed, a leader in laboratory distribution and supply chain solutions, and Curavit Clinical Research, a virtual contract research organization (VCRO) specializing in decentralized clinical trials (DCTs), today announced a strategic collaboration to enhance the efficiency and scalability of kitting and logistics services for clinical research. The combination of Cenmed's expertise in customized kitting, inventory management, and distribution...

Read more
BODYWELLE Teams Up With Local Favorites for Puppy Yoga and Sound Healing in Miami Beach
Healthcare & PharmaceuticalCompany Update

BODYWELLE Teams Up With Local Favorites for Puppy Yoga and Sound Healing in Miami Beach

November 14, 2025 2:30 PM

BODYWELLE, a physician-led longevity and wellness clinic in Miami Beach, will host Puppy Yoga & Sound Healing on Sunday, November 16, 2025, from 9:00 to 11:00 a.m. EST at 1060 Alton Road, Miami Beach. This community-focused wellness event combines restorative yoga, therapeutic sound, and medical-grade self-care experiences in partnership with Go Greek Miami, Pura Vida Miami, Black Sheep Coffee, and Dalmatian Rescue. The morning is designed to...

Read more
Relief Therapeutics Shareholders Approve Business Combination with NeuroX
Healthcare & PharmaceuticalCompany Update

Relief Therapeutics Shareholders Approve Business Combination with NeuroX

November 14, 2025 12:40 PM

RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF, RLFTY) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, announced that shareholders approved by a large majority all resolutions submitted to its extraordinary general meeting (EGM) held earlier today in Geneva, Switzerland. The approvals authorize the business combination between Relief...

Read more

Join the thousands of ACCESS Newswire customers today who are getting millions of views on their news.


Check out our flexible subscription and pay as you go pricing

and packages.

Use Code NEWS10 for 10% off  of your first purchase.


Latest Blog Posts

Visit our blogs for press release tips, media engagement

Strategies, and Product Comparisons.

Executive delivering prepared remarks from an earnings call script
By Jennifer Hammers • July 9, 2026
How to write earnings call prepared remarks that land — structure, length, the safe-harbor open, non-GAAP language, and building remarks around your strategy.
IR
By Brian Balbirnie • July 8, 2026
A practical earnings call preparation checklist for IR teams — the two-week runway, consensus, logistics, Q&A prep, and Reg FD-clean disclosure timing.
ACCESS Newswire guide on AI investor relations — how AI assistants read company earnings disclosures
By Jennifer Hammers • July 6, 2026
AI assistants read your earnings within minutes. Learn how IR teams make disclosures AI-readable — and how the LLM Citation Score measures your visibility.
A logo for accesswire next to a logo for rack
By Jennifer Hammers • June 21, 2026
Compare Muck Rack vs ACCESS Newswire on pricing, features, and alternatives. See how ACCESS Newswire adds distribution, pitching, and analytics.
A blue and white logo with a check mark next to it
By Jennifer Hammers • June 19, 2026
Compare Business Wire vs ACCESS Newswire on pricing and capabilities — and how ACCESS delivers comparable reach at a fraction of the cost.
A blue background with the word access on it
By Jennifer Hammers • June 14, 2026
Compare ACCESS Newswire vs Cision PR Newswire on pricing, features, reach, and reviews — and why companies are making the switch..
Show More




Discover the news
by Industry:


Need help with your PR Strategy?
Learn more about our
professional PR Services today:

.MEDIA PRO 
Want to get noticed
by the Media but don’t
know how? 

.TOTAL PRO

Need full support to 

Optimize your PR

Efforts?